Simonsen Simon Kjær, Nielsen Troels Halfeld, Dalby Rikke Beese, Fialla Annette Dam, Lange Bibi, Tørring Pernille Mathiesen, Diaz Anabel, Kjeldsen Anette Drøhse
Ugeskr Laeger. 2021 May 17;183(20).
Patients with hereditary haemorrhagic telangiectasia (HHT) are known to suffer from cerebral arteriovenous malformations (CAVMs). In this review, we explore existing literature for bleeding risk, interventional therapy and neuroradiological features in HHT-related CAVMs. Studies estimate the annual intracerebral haemorrhage rate of CAVMs in HHT patients to be 0.667-1.014%. The clinician must balance bleeding risk and the non-negligible procedural risks of interventional therapy. We recommend, in agreement with European guidelines, that screening of asymptomatic HHT patients should only be carried out after careful information.
已知患有遗传性出血性毛细血管扩张症（HHT）的患者会罹患脑动静脉畸形（CAVM）。在本综述中，我们探讨了关于HHT相关CAVM的出血风险、介入治疗及神经放射学特征的现有文献。研究估计，HHT患者中CAVM的年脑出血率为0.667%-1.014%。临床医生必须权衡出血风险和介入治疗不可忽视的手术风险。我们与欧洲指南一致建议，仅在提供详细信息后，才应对无症状的HHT患者进行筛查。
